Likewise, findings from the phase 1 CHRYSALIS study indicate that amivantamab, a bispecific EGFR-MET antibody, provides durable antitumor activity in patients with MET exon 14 skipping advanced NSCLC, including those with prior resistance to MET therapies, while maintaining a manageable safety profile [12]. This evidence concerns the gene MET and non-small cell lung carcinoma.